Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Hybrigenics SA (ALHYG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10162
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cancer, chronic lymphocytic leukaemia and moderate to severe psoriasis. The company is also investigating the action of deubiquitinating enzymes (DUB) in the recycling of onco-proteins and the utility of proprietary patented DUB inhibitors against various cancer indications. Hybrigenics’ employs its expertise in DUBs to discover and develop new treatments. It also offers specialized scientific services for validating and inhibiting protein interactions in animal, plant or microbiological cells. Hybrigenics is headquartered in Paris, France.

Hybrigenics SA (ALHYG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Hybrigenics Acquires Genomic Division Of Imaxio 11
Equity Offering 12
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For US$8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For US$4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For US$1.9 Million 19
Hybrigenics SA – Key Competitors 20
Hybrigenics SA – Key Employees 21
Hybrigenics SA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Apr 26, 2018: Hybrigenics Announces Its Full Year 2017 Results 23
Apr 28, 2017: Hybrigenics fuLL year 2016 resuLts 24
Product News 25
03/26/2018: Hybrigenics broad spectrum inhibitor of Ubiquitin-Specific Proteases shows antiviral activity against human adenoviruses 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Hybrigenics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Hybrigenics Acquires Genomic Division Of Imaxio 11
Hybrigenics Raises USD7.8 Million in Rights Offering of Shares 12
Hybrigenics Raises USD7.1 Million in Public Offering 13
Hybrigenics Raises USD2.7 Million in Private Placement 14
Hybrigenics to Raise USD7.6 Million in Rights Offering of Shares 15
Hybrigenics Raises USD6 Million in Private Placement of Shares 16
Hybrigenics Completes Private Placement Of Shares For US$8.4 Million 17
Hybrigenics Completes Private Placement Of Shares For US$4.1 Million 18
Hybrigenics Completes Second Tranche Private Placement Of Shares For US$1.9 Million 19
Hybrigenics SA, Key Competitors 20
Hybrigenics SA, Key Employees 21
Hybrigenics SA, Subsidiaries 22

List of Figures
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Hybrigenics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Hybrigenics SA, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Clark Enterprises Inc:企業の戦略・SWOT・財務分析
    Clark Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Clark Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Casino Guichard-Perrachon SA:戦略・SWOT・企業財務分析
    Casino Guichard-Perrachon SA - Strategy, SWOT and Corporate Finance Report Summary Casino Guichard-Perrachon SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Advicenne SA (ADVIC):製薬・医療:M&Aディール及び事業提携情報
    Summary Advicenne SA (Advicenne) is a developer of pediatric medicines. The company offers product portfolio such as ADV6209, a liquid formulation of a benzodiazepine for moderate sedation and anesthetic premedication; ADV7103, a formulation in the form of micro-tablets for renal tubulopathies. It p …
  • Honeywell International Inc (HON):企業の財務・戦略的SWOT分析
    Honeywell International Inc (HON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Al Mouwasat Medical Services Company (4002):企業の財務・戦略的SWOT分析
    Summary Al Mouwasat Medical Services Company (Mouwasat Medical) is a healthcare service provider that provides health and skincare services. The centre offers services in health care, skin care, and fertility treatment. It provides clinical pharmacy services such as verifying dosages appropriateness …
  • Nexstim Plc (NXTMH)-医療機器分野:企業M&A・提携分析
    Summary Nexstim Plc (Nexstim) is a medical technology company, which focuses on navigated brain stimulation (NBS) to improve rehabilitation in stroke patients non-invasively . Its NBS system, which is FDA cleared and CE-marked, applies navigated transcranial magnetic stimulation (nTMS) device for pr …
  • North Eastern Electric Power Corporation Ltd:発電所・企業SWOT分析
    North Eastern Electric Power Corporation Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inf …
  • Biolase, Inc. (BIOL)-医療機器分野:企業M&A・提携分析
    Summary Biolase, Inc. (Biolase) is medical device company which develops, manufactures, markets and sells dental lasers and related products. It also distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. The company offers two categories of laser s …
  • Windflow Technology Ltd (WTL):企業の財務・戦略的SWOT分析
    Windflow Technology Ltd (WTL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Biotie Therapies Corp-製薬・医療分野:企業M&A・提携分析
    Summary Biotie Therapies Corp (Biotie) is a pharmaceutical company that discovers and develops new medicines for the treatment of various diseases. The company offers products for use in the treatment of neurodegenerative and psychiatric disorders such as parkinson's disease, alzheimer's disease, pr …
  • Keck Seng Investments (Hong Kong) Ltd:企業の戦略・SWOT・財務情報
    Keck Seng Investments (Hong Kong) Ltd - Strategy, SWOT and Corporate Finance Report Summary Keck Seng Investments (Hong Kong) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • CIGNA Corporation:戦略・SWOT・企業財務分析
    CIGNA Corporation - Strategy, SWOT and Corporate Finance Report Summary CIGNA Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Eskom Holdings SOC Limited:企業の戦略・SWOT・財務情報
    Eskom Holdings SOC Limited - Strategy, SWOT and Corporate Finance Report Summary Eskom Holdings SOC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Mithra Pharmaceuticals SA (MITRA):医療機器:M&Aディール及び事業提携情報
    Summary Mithra Pharmaceuticals SA (Mithra) is a developer and manufacturer of over the counter products and prescription drugs for women’s health and other applications. The company offers products such as estelle, donesta, tibelia, zoreline and myring, among others. Its products are used in the tre …
  • Hutchinson SA:企業の戦略的SWOT分析
    Hutchinson SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Pinnacle Entertainment Inc:戦略・SWOT・企業財務分析
    Pinnacle Entertainment Inc - Strategy, SWOT and Corporate Finance Report Summary Pinnacle Entertainment Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • KSK Energy Ventures Ltd (KSK):企業の財務・戦略的SWOT分析
    KSK Energy Ventures Ltd (KSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Securitas AB:企業の戦略・SWOT・財務分析
    Securitas AB - Strategy, SWOT and Corporate Finance Report Summary Securitas AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • McCormick & Company Incorporated:戦略・SWOT・企業財務分析
    McCormick & Company Incorporated - Strategy, SWOT and Corporate Finance Report Summary McCormick & Company Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • RentPath, LLC:企業の戦略・SWOT・財務情報
    RentPath, LLC - Strategy, SWOT and Corporate Finance Report Summary RentPath, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆